{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:07Z","timestamp":1792068847779,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmc.2026.118788","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:10:45Z","timestamp":1787922645000},"page":"118788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Design, synthesis, antitumor estimation, and molecular docking of new imidazothiazolediones as potential dual EGFR and IDO1 inhibitors and apoptosis stimulators"],"prefix":"10.1016","volume":"143","author":[{"given":"Marwa T.","family":"Sarg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-5534","authenticated-orcid":false,"given":"Fatma G.","family":"Abdulrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin S.","family":"Sheta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman S.","family":"Nossier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6594-1766","authenticated-orcid":false,"given":"Ebtehal M.","family":"Husseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.bmc.2026.118788_bb0005","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","article-title":"Updating the definition of cancer","volume":"21","author":"Brown","year":"2023","journal-title":"Mol Cancer Res"},{"issue":"11","key":"10.1016\/j.bmc.2026.118788_bb0010","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3390\/life11111131","article-title":"New insight to overcome tumor resistance: an overview from cellular to clinical therapies","volume":"11","author":"Mitola","year":"2021","journal-title":"Life"},{"issue":"16","key":"10.1016\/j.bmc.2026.118788_bb0015","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.21608\/aijpms.2023.176667.1180","article-title":"Discovery of new quinoxalines as cytotoxic agents: design, synthesis and molecular modeling","volume":"3","author":"Ibrahim","year":"2023","journal-title":"Azhar Int J Pharm Med Sci"},{"issue":"11","key":"10.1016\/j.bmc.2026.118788_bb0025","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3390\/ph13110374","article-title":"Current targeted therapies for the fight against non-small cell lung cancer","volume":"13","author":"Mustachio","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.bmc.2026.118788_bb0030","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12032-022-01744-6","article-title":"A pharmacological exploration of targeted drug therapy in non-small cell lung cancer","volume":"39","author":"Jayan","year":"2022","journal-title":"Med Oncol"},{"issue":"2\u20133","key":"10.1016\/j.bmc.2026.118788_bb0035","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","article-title":"Protein kinases as targets for anticancer agents: from inhibitors to useful drugs","volume":"93","author":"Fabbro","year":"2002","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0040","first-page":"9","article-title":"Design, synthesis and antiproliferative evaluation of novel pyrazolo-pyrimidine derivatives with expected cyclin-dependent kinase 2 inhibitory effect","volume":"2","author":"Younes","year":"2022","journal-title":"Azhar Int J Pharm Med Sci"},{"key":"10.1016\/j.bmc.2026.118788_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105164","article-title":"Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: their relevance for cancer therapy","volume":"161","author":"Liang","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2026.118788_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103811","article-title":"A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy","volume":"99","author":"Ayati","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107037","article-title":"Identification of novel ureido benzothiophenes as dual VEGFR-2\/EGFR anticancer agents","volume":"143","author":"Eldehna","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2026.146138","article-title":"Integrated computational and experimental characterization of a new thiazolidinone EGFR inhibitor with promising anticancer activity","volume":"1366","author":"Elkady","year":"2026","journal-title":"J Mol Struct"},{"issue":"5","key":"10.1016\/j.bmc.2026.118788_bb0065","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1021\/acs.jmedchem.2c01242","article-title":"Targeting the epidermal growth factor receptor with molecular degraders: state-of-the-art and future opportunities","volume":"66","author":"Maity","year":"2023","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118788_bb0070","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1021\/acs.jmedchem.7b01310","article-title":"Recent progress of small-molecule epidermal growth factor receptor (EGFR) inhibitors against C797S resistance in non-small-cell lung cancer","volume":"61","author":"Chen","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138741","article-title":"Pyridine-based glycosides bearing 1,2,4-triazole and their 1,3,4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: design, synthesis, antiproliferative activity and in silico studies","volume":"1313","author":"Kassem","year":"2024","journal-title":"J Mol Struct"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73171-8","article-title":"Novel quinazolin-4-one based derivatives bearing 1,2,3-triazole and glycoside moieties as potential cytotoxic agents through dual EGFR and VEGFR-2 inhibitory activity","volume":"14","author":"Abdel-Rahman","year":"2024","journal-title":"Sci Rep"},{"issue":"24","key":"10.1016\/j.bmc.2026.118788_bb0085","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1080\/17568919.2024.2431475","article-title":"New pyrano-pyridine conjugates as potential anticancer agents: design, synthesis and computational studies","volume":"16","author":"Srour","year":"2024","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137790","article-title":"Anticancer activity of new triazolopyrimidine linked coumarin and quinolone hybrids: synthesis, molecular modeling, TrkA, PI3K\/AKT and EGFR inhibition","volume":"1305","author":"Batran","year":"2024","journal-title":"J Mol Struct"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0095","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21608\/aijpms.2024.294539.1271","article-title":"Synthesis, biological assessment, and docking study of new pyrazolo[1,5-a]pyrimidine derivatives with potential anticancer activity","volume":"5","author":"Shafei","year":"2025","journal-title":"Azhar Int J Pharm Med Sci"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00280-009-1174-7","article-title":"Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors","volume":"66","author":"Choi","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"10.1016\/j.bmc.2026.118788_bb0105","first-page":"2609","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins","volume":"118","author":"Guix","year":"2008","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.bmc.2026.118788_bb0110","doi-asserted-by":"crossref","first-page":"10100","DOI":"10.1158\/0008-5472.CAN-06-1684","article-title":"Heterodimerization of insulin-like growth factor receptor\/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib","volume":"66","author":"Morgillo","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmc.2026.118788_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133971","article-title":"Modified pyrido[2,3-d]pyrimidin-4(3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: design, synthesis, and anti-cancer evaluation","volume":"1270","author":"Nossier","year":"2022","journal-title":"J Mol Struct"},{"issue":"3","key":"10.1016\/j.bmc.2026.118788_bb0120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol"},{"issue":"4","key":"10.1016\/j.bmc.2026.118788_bb0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/1040841X.2012.742037","article-title":"Persistent infectious diseases say \u2013 IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy","volume":"40","author":"Barth","year":"2014","journal-title":"Crit Rev Microbiol"},{"issue":"22","key":"10.1016\/j.bmc.2026.118788_bb0130","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1021\/acs.jmedchem.5b00461","article-title":"Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway","volume":"58","author":"Dounay","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4137\/IJTR.S38355","article-title":"The kynurenine pathway is a double-edged sword in immune-privileged sites and in cancer: implications for immunotherapy","volume":"9","author":"Routy","year":"2016","journal-title":"Int J Tryptophan Res"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bbrc.2005.09.032","article-title":"Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism","volume":"338","author":"Takikawa","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0145","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1073\/pnas.0610007104","article-title":"Molecular insights into substrate recognition and catalysis by tryptophan 2,3-dioxygenase","volume":"104","author":"Forouhar","year":"2007","journal-title":"Proc Natl Acad Sci"},{"issue":"22","key":"10.1016\/j.bmc.2026.118788_bb0150","doi-asserted-by":"crossref","first-page":"6985","DOI":"10.1158\/1078-0432.CCR-11-1331","article-title":"Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives","volume":"17","author":"Godin-Ethier","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.bmc.2026.118788_bb0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1172\/JCI31178","article-title":"Indoleamine 2,3-dioxygenase and tumor-induced tolerance","volume":"117","author":"Munn","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0160","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-065X.2008.00610.x","article-title":"Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape","volume":"222","author":"Katz","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bmc.2026.118788_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114860","article-title":"Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors","volume":"245","author":"Zhou","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.molstruc.2019.04.048","article-title":"Design, synthesis, molecular docking and biological screening of N-ethyl-N-methylbenzenesulfonamide derivatives as effective antimicrobial and antiproliferative agents","volume":"1194","author":"Abd El-Gilil","year":"2019","journal-title":"J Mol Struct"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0175","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"01","key":"10.1016\/j.bmc.2026.118788_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2167-7662.1000151","article-title":"Imidazo[2,1b ]thiazole: introduction, current and perspective","volume":"06","author":"Leoni","year":"2017","journal-title":"Bioenerg Open Access"},{"issue":"5","key":"10.1016\/j.bmc.2026.118788_bb0185","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0223-5234(87)90037-7","article-title":"Imidazo[2,1-b]thiazoles: analogues du l\u00e9vamisole","volume":"22","author":"Amarouch","year":"1987","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107935","article-title":"Synthesis of S-alkylated oxadiazole bearing imidazo[2,1-b]thiazole derivatives targeting breast cancer: in vitro cytotoxic evaluation and in vivo radioactive tracing studies","volume":"153","author":"Mohammed","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105151","article-title":"Design, synthesis and biological evaluation of 2,3-dihydroimidazo[2,1-b]thiazoles as dual EGFR and IGF1R inhibitors","volume":"115","author":"Gadekar","year":"2021","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114661","article-title":"New thiazole-based derivatives as EGFR\/HER2 and DHFR inhibitors: synthesis, molecular modeling simulations and anticancer activity","volume":"241","author":"Sabry","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107538","article-title":"Synthesis, molecular modeling simulations and anticancer activity of some new Imidazo[2,1-b]thiazole analogues as EGFR\/HER2 and DHFR inhibitors","volume":"150","author":"Moharram","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116698","article-title":"Design, synthesis and biological evaluation of a new series of imidazothiazole-hydrazone hybrids as dual EGFR and Akt inhibitors for NSCLC therapy","volume":"276","author":"Alt\u0131ntop","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2026.118788_bb0215","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1021\/ml500247w","article-title":"Crystal structures and structure\u2013activity relationships of imidazothiazole derivatives as IDO1 inhibitors","volume":"5","author":"Tojo","year":"2014","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2026.118788_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129532","article-title":"Imidazo[2,1-b]thiazole based indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor: structure based design, synthesis, bio-evaluation and docking studies","volume":"96","author":"Singh","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.bmc.2026.118788_bb0225","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00706-025-03375-9","article-title":"5-Phosphonohydantoins: synthesis and investigation of their biological activities","volume":"156","author":"Klimchuk","year":"2025","journal-title":"Monatsh Chem"},{"issue":"6","key":"10.1016\/j.bmc.2026.118788_bb0230","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1021\/jo052576i","article-title":"On formation of tiohydantoins from amino acids under acylation conditions","volume":"71","author":"Reyes","year":"2006","journal-title":"J Organomet Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0235","first-page":"3649","article-title":"Thiohydantoins: selective N- and S-functionalization for Liebeskind-Srogl reaction study","volume":"22","author":"Gosling","year":"2011","journal-title":"Synthesis-Stuttgart"},{"key":"10.1016\/j.bmc.2026.118788_bb0240","doi-asserted-by":"crossref","unstructured":"Arce EM, Lamont SG, Davies PW, et al. Sulfenyl ynamides in gold catalysis: synthesis of oxo-functionalised 4-aminoimidazolyl fused compounds by intermolecular annulation reactions. Adv Synth Catal 2020;362(12):2503\u20132509. doi:https:\/\/doi.org\/10.1002\/adsc.202000134.","DOI":"10.1002\/adsc.202000134"},{"key":"10.1016\/j.bmc.2026.118788_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107471","article-title":"Novel imidazolone derivatives as potential dual inhibitors of checkpoint kinases 1 and 2: design, synthesis, cytotoxicity evaluation, and mechanistic insights","volume":"149","author":"Sheta","year":"2024","journal-title":"Bioorg Chem"},{"issue":"August","key":"10.1016\/j.bmc.2026.118788_bb0250","article-title":"Design, synthesis, radiolabeling, and mechanistic insights of hydrazinyl imidazolones as broad spectrum antitumor agents with potential carbonic anhydrase inhibition: in vitro, in vivo, and in silico studies","volume":"298","author":"Husseiny","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"13","key":"10.1016\/j.bmc.2026.118788_bb0255","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1016\/j.bmc.2005.04.024","article-title":"Synthesis of 2-(aminocarbonylmethylthio)-1H-imidazoles as novel Capravirine analogues","volume":"13","author":"Loksha","year":"2005","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2026.118788_bb0260","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/jhet.1631","article-title":"Utilization of 2-Chloronicotinonitrile in the syntheses of novel fused bicyclic and polynuclear heterocycles of anticipated antitumor activity","volume":"53","author":"Hamama","year":"2016","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejmech.2016.07.022","article-title":"Synthesis, anticancer activity and photostability of novel 3-ethyl-2-mercapto-thieno[2,3-d]pyrimidin-4(3H)-ones","volume":"123","author":"Mavrova","year":"2016","journal-title":"Eur J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0270","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jhet.3423","article-title":"Synthesis of some novel furan-tagged Thienopyrimidine derivatives as antibacterial agents","volume":"56","author":"Abdel Hamid","year":"2019","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133529","article-title":"Novel pyrazole-oxadiazole hybrids possessing methanesulphonyl pharmacophore with good gastric safety profile: design, synthesis, cyclooxygenase inhibition, anti-inflammatory activity and histopathological studies","volume":"1266","author":"Abdellatif","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118788_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134489","article-title":"Antiproliferative and antimicrobial studies of novel organic-inorganic nanohybrids of ethyl 2-((5-methoxy-1H-benzo[d]imidazol-2-yl)thio)acetate (EMBIA) with TiO2 and ZnO","volume":"1274","author":"Alheety","year":"2023","journal-title":"J Mol Struct"},{"issue":"4","key":"10.1016\/j.bmc.2026.118788_bb0285","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/10426507.2016.1247087","article-title":"Regioselective synthesis, antitumor and antioxidant activities of some 1,2,4-triazole derivatives based on 4-phenyl-5-(quinolin-8-yloxy)methyl-4 H -1,2,4-triazole-3-thiol","volume":"192","author":"Behalo","year":"2017","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"issue":"5","key":"10.1016\/j.bmc.2026.118788_bb0290","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jhet.2250","article-title":"Synthesis and aqnti-cancer activity of 1,3,4-thiadiazole and 1,3-thiazole derivatives having 1,3,4-oxadiazole moiety","volume":"52","author":"Dawood","year":"2015","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133817","article-title":"A new thiazoldinone and triazole derivatives: synthesis, characterization and liquid crystalline properties","volume":"1270","author":"Tomma","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118788_bb0300","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1007\/s00044-010-9392-4","article-title":"Synthesis characterization and biological evaluation of some alkoxyphthalimide derivatives of 3-(4-substituted phenyl)-6, 6-diphenyl-3,3a-dihydro-2H-imidazo[2,1-b]pyrazolo[3,4-d] [1,3]thiazol-7(6H)-one","volume":"20","author":"Dangi","year":"2011","journal-title":"Med Chem Res"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0305","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17415993.2011.643550","article-title":"Thiohydantoins: synthetic strategies and chemical reactions","volume":"33","author":"Metwally","year":"2012","journal-title":"J Sulfur Chem"},{"issue":"12","key":"10.1016\/j.bmc.2026.118788_bb0310","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/jhet.4551","article-title":"Ultrasonic-assisted condensation of aromatic and aliphatic aldehydes with 3-(thiophen-2-yl)-5-pyrazolone: synthesis, characterization and stereoselective application","volume":"59","author":"Rizk","year":"2022","journal-title":"J Heterocyclic Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135453","article-title":"New benzylidene festooned thiazolidinone-coumarin molecular hybrids targeting human breast adenocarcinoma cells: design, synthesis, SAR, molecular modelling and biological evaluation as CDK2 inhibitors","volume":"1285","author":"Manda","year":"2023","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2026.118788_bb0320","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","article-title":"Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines","volume":"83","author":"Monks","year":"1991","journal-title":"J Natl Cancer Inst"},{"issue":"1_2","key":"10.1016\/j.bmc.2026.118788_bb0325","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assayss","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"issue":"12","key":"10.1016\/j.bmc.2026.118788_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11121826","article-title":"Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials","volume":"11","author":"Maennling","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmc.2026.118788_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers (2017)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0340","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000492849","article-title":"The clinicopathological and prognostic significance of IDO1 expression in human solid tumors: evidence from a systematic review and meta-analysis","volume":"49","author":"Yu","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0345","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.bmc.2026.118788_bb0350","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/s41379-018-0061-3","article-title":"IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1","volume":"31","author":"Dill","year":"2018","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.bmc.2026.118788_bb0355","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1097\/PAS.0000000000001099","article-title":"Indoleamine-2,3-dioxygenase in non-small cell lung cancer: a targetable mechanism of immune resistance frequently coexpressed with PD-L1","volume":"42","author":"Volaric","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.bmc.2026.118788_bb0360","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis flow cytometric detection of phosphatidylserine early apoptotic cells using fluorescein labelled expression on annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.bmc.2026.118788_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133926","article-title":"Chemical synthesis and molecular docking study of new thiazole, thiophene, and thieno[2,3-d]pyrimidine derivatives as potential antiproliferative and antimicrobial agents","volume":"1270","author":"Othman","year":"2022","journal-title":"J Mol Struct"},{"issue":"48","key":"10.1016\/j.bmc.2026.118788_bb0370","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-Anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.bmc.2026.118788_bb0375","doi-asserted-by":"crossref","first-page":"17319","DOI":"10.1021\/acs.jmedchem.4c01223","article-title":"Discovery of novel PROTAC SIRT6 degraders with potent efficacy against hepatocellular carcinoma","volume":"67","author":"Huang","year":"2024","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmc.2026.118788_bb0380","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ddr.430340203","article-title":"Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen","volume":"34","author":"Boyd","year":"1995","journal-title":"Drug Dev Res"},{"issue":"25","key":"10.1016\/j.bmc.2026.118788_bb0385","doi-asserted-by":"crossref","first-page":"12206","DOI":"10.1039\/D2NJ02061K","article-title":"Rationale design, synthesis, cytotoxicity evaluation, and in silico mechanistic studies of novel 1,2,3-triazoles with potential anticancer activity","volume":"46","author":"Othman","year":"2022","journal-title":"New J Chem"},{"issue":"14","key":"10.1016\/j.bmc.2026.118788_bb0390","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.4155\/fmc-2023-0139","article-title":"Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors","volume":"15","author":"Husseiny","year":"2023","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105968","article-title":"The effect of novel synthetic semicarbazone- and thiosemicarbazone-linked 1,2,3-triazoles on the apoptotic markers, VEGFR-2, and cell cycle of myeloid leukemia","volume":"127","author":"Othman","year":"2022","journal-title":"Bioorg Chem"},{"issue":"4","key":"10.1016\/j.bmc.2026.118788_bb0400","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14728222.11.4.463","article-title":"The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implications","volume":"11","author":"Nakamura","year":"2007","journal-title":"Expert Opin Ther Targets"},{"issue":"9","key":"10.1016\/j.bmc.2026.118788_bb0405","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1177\/1087057114536616","article-title":"High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes","volume":"19","author":"Seegers","year":"2014","journal-title":"J Biomol Screen"},{"key":"10.1016\/j.bmc.2026.118788_bb0410","doi-asserted-by":"crossref","first-page":"28.6.1","DOI":"10.1002\/0471142727.mb2806s111","article-title":"Assaying cell cycle status using flow cytometry","volume":"111","author":"Kim","year":"2015","journal-title":"Curr Protoc Mol Biol"},{"issue":"24","key":"10.1016\/j.bmc.2026.118788_bb0415","doi-asserted-by":"crossref","first-page":"11565","DOI":"10.1039\/D3NJ01638B","article-title":"Mimicry of sorafenib: novel diarylureas as VEGFR2 inhibitors and apoptosis inducers in breast cancer","volume":"47","author":"Ismail","year":"2023","journal-title":"New J Chem"},{"issue":"1","key":"10.1016\/j.bmc.2026.118788_bb0420","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2026.2656826","article-title":"Design, synthesis, anticancer activity, and mechanistic investigation of 4,5,6,7-tetrahydrobenzo[ b ]thiophene carboxamides as CDK-2 inhibitors: in vitro and in silico DFT and molecular docking study","volume":"41","author":"Anwer","year":"2026","journal-title":"J Enzyme Inhib Med Chem"},{"key":"10.1016\/j.bmc.2026.118788_bb0425","first-page":"1","article-title":"Design, synthesis, anticancer estimation, and computational studies of novel benzochromenoimidazopyrimidines as CDK-2 inhibitors and apoptosis stimulators","author":"Abdulrahman","year":"2026","journal-title":"Mol Divers"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626002440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:36:18Z","timestamp":1792067778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626002440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":85,"alternative-id":["S0968089626002440"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118788","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, antitumor estimation, and molecular docking of new imidazothiazolediones as potential dual EGFR and IDO1 inhibitors and apoptosis stimulators","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118788"}}